Eptifibatide after clot-dissolving treatment in stroke patients seen late
Tests eptifibatide after clot-dissolving treatment in adults with ischemic stroke.
Plain-language title generated from the registry record
Registry title: Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis
Key facts
- Where
- Chongqing, Ganzhou, Haikou, Ji’an, and Nanchang, ChinaSee the 6 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an ischemic stroke who arrived at hospital 4.5 to 24 hours after last being well and did not improve, or got worse, after clot-dissolving treatment (thrombolysis) through a vein.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Acute ischemic stroke, with 4.5 to 24 hours from last known well to hospital arrival. NIHSS score of 4 or more before randomization. If a large or medium vessel is blocked, the NIHSS score must also be 10 or less.
- Earlier treatment
- Must have finished standard intravenous thrombolysis. Afterwards: no clear improvement within 1 hour, or worsening within 1 hour, or a rise in NIHSS score of 2 points or more within 24 hours of onset. The study drug must be given within 60 minutes after thrombolysis.
Main reasons for not taking part
- Bleeding in the brain on CT or MRI
- Planned endovascular therapy
- A definite heart source of blood clots, such as atrial fibrillation or a mechanical heart valve
- Pre-stroke modified Rankin Scale score of 2 or more
- Pregnancy or breastfeeding
Read by machine on 9 November 2026.
Where in China
- Xinqiao Hospital and The Second Affiliated HospitalChongqing, ChinaContact: Zhongming QiuNo longer taking part
- Ganzhou People's HospitalGanzhou, ChinaContact: Guoyong ZengNo longer taking part
- The First Affiliated Hospital of Gannan Medical UniversityGanzhou, ChinaContact: Qiujiang XiNo longer taking part
- The First Affiliated Hospital of Hainan Medical UniversityHaikou, ChinaContact: Zhenqiang ZhaoNo longer taking part
- The Affiliated Hospital of Jinggangshan UniversityJi’an, ChinaContact: Yongcheng ZhangNo longer taking part
- The First Affiliated Hospital of NanChang UniversityNanchang, ChinaContact: Daojun Hong, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Xinqiao Hospital of Chongqing
- Trial code
- NCT07347626
- Record updated
- 16 January 2026
- Original description
This is a multicenter, randomized, open-label, blinded-endpoint clinical trial designed to evaluate the efficacy and safety of early administration of eptifibatide following intravenous thrombolysis in patients with acute ischemic stroke who present 4.5 to 24 hours after symptom onset.Read full original descriptionShow less
Efficacy and Safety of Eptifibatide Therapy Following Intravenous Thrombolysis in Acute Ischemic Stroke Patients Within 4.5 to 24 Hours After Onset: A Multicenter, Randomized Controlled Trial
This is a multicenter, randomized, open-label, blinded-endpoint clinical trial designed to evaluate the efficacy and safety of early administration of eptifibatide following intravenous thrombolysis in patients with acute ischemic stroke who present 4.5 to 24 hours after symptom onset.
Inclusion: Age ≥ 18 years; Acute ischemic stroke, with the time interval from last known well to hospital presentation being 4.5 to 24 hours; NIHSS score ≥ 4 before randomization; if large or medium vessel occlusion is present, an NIHSS score ≤ 10 is also required; Presence of any of the following conditions after completion of standard intravenous thrombolysis:; No significant neurological improvement within 1 hour (defined as a change in NIHSS score ≤ 1 point from baseline); Early neurological deterioration within 1 hour of onset (defined as an increase in NIHSS score ≥ 2 points from baseline); Neurological fluctuation within 24 hours after symptom onset (defined as an increase in NIHSS score ≥ 2 points from the lowest value post-thrombolysis); Ability to receive the assigned study drug within 60 minutes after intravenous thrombolysis; Signed written informed consent obtained from the patient or their legal representative.
Exclusion: Planned endovascular therapy; Intracranial hemorrhage confirmed by CT or MRI; Pre-stroke modified Rankin Scale (mRS) score ≥ 2; Allergy to eptifibatide, other glycoprotein IIb/IIIa inhibitors, aspirin, or clopidogrel; History of non-atherosclerotic arteriopathy, including moyamoya disease, arterial dissection, or fibromuscular dysplasia; Pre-existing neurological or psychiatric disease that would preclude accurate neurological assessment; History of bleeding diathesis, severe cardiac disease, liver disease, or sepsis; Any terminal illness with life expectancy < 6 months; Presence of any definite cardioembolic source, including: chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, endocarditis, intracardiac thrombus or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, spontaneous echo contrast in the left atrium, or ejection fraction < 30%; Renal insufficiency (glomerular filtration rate < 30 ml/min or serum creatinine > 220 μmol/L [2.5 mg/dL]); Platelet count < 100 × 10⁹/L; Known hypercoagulable state; Pregnancy or lactation; Brain tumor with mass effect on imaging (except for small meningiomas); Evidence of intracranial arteriovenous malformation or aneurysm with diameter > 5 mm on CT or MR angiography; Current participation in another clinical trial; Anticipated inability to complete follow-up.